Serum Level of Soluble Fibrinogen-Like Protein 2 in Renal Allograft Recipients with Acute Rejection: a Preliminary Study.

Z. Zhao,C. Yang,Q. Tang,T. Zhao,Y. Jia,Z. Ma,R. Rong,M. Xu,T. Zhu
DOI: https://doi.org/10.1016/j.transproceed.2012.05.082
IF: 1.014
2012-01-01
Transplantation Proceedings
Abstract:Background. Soluble fibrinogen-like protein 2 (sfg12), which is mainly secreted by T cells, is a novel effector of regulatory T cells with immunosuppressive functions. The aim of this study was to investigate serum levels of sfg12 among renal allograft recipients. Methods. From November 2010 to August 2011 we retrospectively divided 47 renal allograft recipients into an acute rejection (n = 19) versus a stable group (n = 28) according to allograft biopsy results, using the Banff 2007 classification. The acute rejection group was subdivided into grade I (n = 8) versus grade II T-cell mediated (n = 6) or antibody-mediated rejection episodes (n = 5). Peripheral blood samples were collected at the time of biopsy. Fourteen healthy volunteers were included as normal group controls. Serum levels of sfg12 were analyzed by enzyme-linked immunosorbent assay. Results. Serum levels of sfg12 were increased among renal allograft recipients suffering from biopsy-proven acute rejection episodes (61.91 +/- 45.68 ng/mL), versus those with stable allografts (38.59 +/- 19.92 ng/mL, P < .05) or healthy volunteers (29.10 +/- 18.08 ng/mL, P < .05). The sfg12 level was significantly higher among patients with antibody-mediated (118.48 +/- 55.54 ng/mL) than T-cell mediated acute rejection episodes (41.71 +/- 16.44 ng/mL, P < .01). Serum sfg12 levels were remarkably elevated in patients with grade II (51.87 +/- 19.13 ng/mL) versus grade IT-cell mediated rejection (34.10 +/- 9.26 ng/mL,P < .05). Conclusions. Serum sfg12 levels were increased among renal allograft recipients with acute rejection episodes to an extent dependent upon the pathological type and severity of the response.
What problem does this paper attempt to address?